Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Recommendation of “Buy” from Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given an average rating of “Buy” by the six ratings firms that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $20.25.

Several equities analysts have recently commented on ZVRA shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research note on Wednesday. HC Wainwright upped their price target on Zevra Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 5th.

Zevra Therapeutics Trading Up 2.0 %

NASDAQ:ZVRA opened at $7.13 on Friday. The firm has a market capitalization of $298.41 million, a P/E ratio of -5.18 and a beta of 1.97. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.88. The company has a fifty day moving average of $5.59 and a 200 day moving average of $5.51. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $8.44.

Insider Buying and Selling

In related news, Director Thomas Anderson acquired 10,000 shares of the stock in a transaction on Tuesday, July 16th. The stock was acquired at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the acquisition, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $136,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders purchased a total of 22,000 shares of company stock valued at $140,340 over the last three months. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Zevra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ZVRA. International Assets Investment Management LLC lifted its holdings in Zevra Therapeutics by 555.0% in the fourth quarter. International Assets Investment Management LLC now owns 6,550 shares of the company’s stock worth $43,000 after buying an additional 5,550 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Zevra Therapeutics by 134.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company’s stock worth $63,000 after buying an additional 5,545 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in Zevra Therapeutics in the first quarter worth about $64,000. The Manufacturers Life Insurance Company lifted its holdings in Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after buying an additional 2,452 shares during the period. Finally, IFG Advisors LLC lifted its holdings in Zevra Therapeutics by 45.0% in the first quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after buying an additional 5,800 shares during the period. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.